Literature DB >> 26729829

An unusual response with long term survival using erlotinib in NSCLC lung with brain metastases.

Madhup Rastogi1, Sambit Swarup Nanda1, Chandra Prakash1, Dinkar Kulshreshtha2.   

Abstract

We present a case of a middle-aged woman with adenocarcinoma of the lung and metastatic brain lesions. In view of her poor general condition and poor compliance to first-line chemotherapy, the patient was kept on tablet erlotinib after whole brain radiotherapy. This novel treatment resulted in a dramatic response with radiological regression in both the primary lung lesion and metastatic intracranial lesions translating in unexpected and ongoing 24-month survival. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26729829      PMCID： PMC4716384          DOI： 10.1136/bcr-2015-213239

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  14 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.

Authors:  David M Jackman; Beow Y Yeap; Neal I Lindeman; Panos Fidias; Michael S Rabin; Jennifer Temel; Arthur T Skarin; Matthew Meyerson; Alison J Holmes; Ana M Borras; Boris Freidlin; Patricia A Ostler; Joan Lucca; Thomas J Lynch; Bruce E Johnson; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

3.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Authors:  Masahiro Fukuoka; Yi-Long Wu; Sumitra Thongprasert; Patrapim Sunpaweravong; Swan-Swan Leong; Virote Sriuranpong; Tsu-Yi Chao; Kazuhiko Nakagawa; Da-Tong Chu; Nagahiro Saijo; Emma L Duffield; Yuri Rukazenkov; Georgina Speake; Haiyi Jiang; Alison A Armour; Ka-Fai To; James Chih-Hsin Yang; Tony S K Mok
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

4.  Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003.

Authors:  Ping Yang; Mark S Allen; Marie C Aubry; Jason A Wampfler; Randolph S Marks; Eric S Edell; Stephen Thibodeau; Alex A Adjei; James Jett; Claude Deschamps
Journal:  Chest       Date:  2005-07       Impact factor: 9.410

5.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Authors:  David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Jänne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy A Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

6.  The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.

Authors:  Hao Bai; Baohui Han
Journal:  Am J Clin Oncol       Date:  2013-04       Impact factor: 2.339

7.  Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.

Authors:  J B Sørensen; H H Hansen; M Hansen; P Dombernowsky
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

8.  Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

Authors:  James W Welsh; Ritsuko Komaki; Arya Amini; Mark F Munsell; Wyatt Unger; Pamela K Allen; Joe Y Chang; Jeffrey S Wefel; Susan L McGovern; Linda L Garland; Su S Chen; Jamie Holt; Zhongxing Liao; Paul Brown; Erik Sulman; John V Heymach; Edward S Kim; Baldassarre Stea
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

9.  A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.

Authors:  Paul W Sperduto; Meihua Wang; H Ian Robins; Michael C Schell; Maria Werner-Wasik; Ritsuko Komaki; Luis Souhami; Mark K Buyyounouski; Deepak Khuntia; William Demas; Sunjay A Shah; Lucien A Nedzi; Gad Perry; John H Suh; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-04       Impact factor: 7.038

10.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.